ArticleVirus research2017
Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.
Article in Virus research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Broad-Spectrum Antiviral Activity of Cyclophilin Inhibitors Against Coronaviruses: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Non-Immunosuppressive Cyclophilin Inhibitors.Angewandte Chemie (International ed. in English) · 2022Review
- Review
- A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease.Saudi journal of biological sciences · 2022Review
- Optimized Protocols for the Propagation and Quantification of Infectious Murine Hepatitis Virus (MHV-A59) Using NCTC Clone 1469 and 929 Cells.Methods and protocols · 2022Article
- The Cyclophilin-Dependent Calcineurin Inhibitor Voclosporin Inhibits SARS-CoV-2 Replication in Cell Culture.Transplant international : official journal of the European Society for Organ Transplantation · 2022Article
- A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets.PLoS biology · 2021Article
- Recent advances in potential drug therapies combating COVID-19 and related coronaviruses-A perspective.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.Medicinal research reviews · 2021Review
- SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.Expert opinion on therapeutic patents · 2021Review
- Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2.Transboundary and emerging diseases · 2021Review
- An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses.International immunopharmacology · 2021Review
- Therapeutic approaches against coronaviruses acute respiratory syndrome.Pharmacology research & perspectives · 2021Review
- MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges.Annals of clinical microbiology and antimicrobials · 2021Review
- Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.Frontiers in pharmacology · 2021Review
- The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2.Journal of virology · 2020Article
- Cyclosporine and COVID-19: Risk or favorable?American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Currently, there is no registered treatment for infections with emerging zoonotic coronaviruses like SARS- and MERS-coronavirus. We here report that in cultured cells low-micromolar concentrations of alisporivir, a non-immunosuppressive cyclosporin A-analog, inhibit the replication of four different coronaviruses, including MERS- and SARS-coronavirus. Ribavirin was found to further potentiate the antiviral effect of alisporivir in these cell culture-based infection models, but this combination treatment was unable to improve the outcome of SARS-CoV infection in a mouse model. Nevertheless, our data provide a basis to further explore the potential of Cyp inhibitors as host-directed, broad-spectrum inhibitors of coronavirus replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.